- Home
- UBS vs TMO Comparison
UBS vs TMO Comparison
Compare UBS & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBS | TMO |
|---|---|---|
| Founded | 1862 | 1956 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.1B | 164.3B |
| IPO Year | 2014 | 1996 |
Fundamental Metrics
Financial Performance| Metric | UBS | TMO |
|---|---|---|
| Price | $49.36 | $492.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 18 |
| Target Price | $60.30 | ★ $636.00 |
| AVG Volume (30 Days) | ★ 2.2M | 2.1M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.29% | 0.40% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | N/A | ★ 4.43 |
| Revenue | N/A | ★ $20,918,000,000.00 |
| Revenue This Year | $7.40 | $6.55 |
| Revenue Next Year | $2.83 | $5.11 |
| P/E Ratio | ★ $17.22 | $105.95 |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $32.69 | $401.45 |
| 52 Week High | $51.24 | $643.99 |
Technical Indicators
Market Signals| Indicator | UBS | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 58.30 |
| Support Level | $46.47 | $456.87 |
| Resistance Level | N/A | $491.73 |
| Average True Range (ATR) | 0.81 | 12.86 |
| MACD | 0.03 | 0.48 |
| Stochastic Oscillator | 57.19 | 87.54 |
Price Performance
Historical ComparisonAbout UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).